At the shareholders' meeting on May 28, Anxo Pharmaceutical Chairman Chien-Chih Wang expressed optimism about the company's operations in the second half of the year and into next year, citing the strong growth potential of three major products in the Taiwan market—Tang An De (a diabetes medication), a smoking cessation aid, and a gynecological drug in China. He also highlighted the company’s progress in overseas licensing and collaborative development efforts as a positive turning point for overall business performance.
Read more
